Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial Publisher Pubmed

Mohammadinejad P¹ ; Arya P¹ ; Esfandbod M¹ ; Kaviani A¹ ; Najafi M¹ ; Kashani L¹ ; Zeinoddini A¹ ; Emami SA¹ ; Akhondzadeh S¹

Show Affiliations

1. Tehran University of Medical Sciences, Tehran, Iran

Source: Annals of Pharmacotherapy Published:2015

Abstract

Background: Depression is a well-known complication of breast cancer, which is known to adversely affect quality of life, prognosis, and survival in breast cancer patients. Celecoxib, a nonsteroidal anti-inflammatory drug, which acts via the selective inhibition of cyclo-oxygenase (COX)-2, has been shown to have antidepressive effects. Objectives: Here, we aimed to compare the efficacy and safety of celecoxib, a selective inhibitor of COX-2, with diclofenac, a nonselective inhibitor of both COX-1 and COX-2 in reducing depressive symptoms and pain in breast cancer patients. Methods: A total of 52 outpatients with breast cancer with mild to moderate depression, who suffered from pain and needed analgesics, participated in the trial and underwent 6 weeks of treatment with either celecoxib (200 mg twice daily) or diclofenac (50 mg twice daily). Participants were investigated using the Hamilton Depression Rating Scale (HDRS). The primary outcome measure was to compare the antidepressant effects of celecoxib and diclofenac. Results: Repeated-measures analysis demonstrated significant effect for Time Afa€” Treatment interaction on the HDRS scores: F(1.76, 87.85) = 9.66; P < 0.001. By study conclusion, greater improvement was observed in the HDRS score of the celecoxib group compared with the diclofenac group (P = 0.002). No one experienced remission (HDRS A¢a€°A¤ 7) in either group. Frequencies of adverse events were not significantly different between groups. Conclusion: Celecoxib seems to possess superior antidepressive effects compared with diclofenac in breast cancer patients with mild to moderate depression. © 2015, SAGE Publications. All rights reserved.

Related Docs

View other Related Docs

1. Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients With Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial, Psychiatry Research (2017)

2. Celecoxib for the Treatment of Mild-To-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2015)

3. Celecoxib Adjunctive Therapy for Acute Bipolar Mania: A Randomized, Double-Blind, Placebo-Controlled Trial, Bipolar Disorders (2015)

4. Therapeutic Effects of Minocycline on Mild-To-Moderate Depression in Hiv Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, International Clinical Psychopharmacology (2016)

5. Effect of Adjunctive Celecoxib on Bdnf in Manic Patients Undergoing Electroconvulsive Therapy: A Randomized Double Blind Controlled Trial, Pharmacopsychiatry (2015)

6. Efficacy and Safety of Celecoxib for Treatment of Mild to Moderate Postpartum Depression: A Randomized, Double-Blind, Placebo-Controlled Trial, Archives of Gynecology and Obstetrics (2024)

7. Acetaminophen As Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Iranian Journal of Psychiatry (2018)

8. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study, Pharmacopsychiatry (2016)

Experts (# of related papers)

View all Related Experts

Shahin Akhondzadeh Basti (32)

Farzin Rezaei (6)

Other Related Docs

9. Pioglitazone Adjunctive Therapy for Depressive Episode of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Depression and Anxiety (2015)

10. Efficacy and Safety of Pentoxifylline Combination Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2021)

11. The Effects of Pioglitazone Adjuvant Therapy on Negative Symptoms of Patients With Chronic Schizophrenia: A Double-Blind and Placebo-Controlled Trial, Human Psychopharmacology (2016)

12. A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents With Acute Bipolar Mania, Journal of Child and Adolescent Psychopharmacology (2017)

13. Review of Clinical Studies Targeting Inflammatory Pathways for Individuals With Autism, Frontiers in Psychiatry (2019)

14. Comparison of Saffron Versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial, Pharmacopsychiatry (2017)

15. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)

16. Riluzole Combination Therapy for Moderate-To-Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychiatric Research (2016)

17. Simvastatin As an Adjuvant Therapy to Fluoxetine in Patients With Moderate to Severe Major Depression: A Double-Blind Placebo-Controlled Trial, Journal of Psychopharmacology (2015)

18. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical Neuropharmacology (2017)

19. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)

20. Simvastatin Adjunct Therapy for Negative Symptoms of Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial, International Clinical Psychopharmacology (2017)

21. Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Affective Disorders (2015)

22. Celecoxib in Treatment of Postpartum Depression: A Case Report, Archives of Iranian Medicine (2023)

23. Celecoxib As an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial, Pharmacopsychiatry (2015)

24. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, International Journal of Neuropsychopharmacology (2020)

25. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)

26. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Clinical Neuropharmacology (2019)

27. Cilostazol Adjunctive Therapy in Treatment of Negative Symptoms in Chronic Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Study, Human Psychopharmacology (2017)

28. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)

29. Palmitoylethanolamide As Adjunctive Therapy in Major Depressive Disorder: A Double-Blind, Randomized and Placebo-Controlled Trial, Journal of Affective Disorders (2018)

30. Citicoline (Cdp-Choline) Add-On Therapy to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, Human Psychopharmacology (2018)

31. Riluzole for Treatment of Men With Methamphetamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Psychopharmacology (2019)

32. Minocycline As Adjunctive Treatment to Risperidone in Children With Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial, Journal of Child and Adolescent Psychopharmacology (2016)

33. Monoclonal Antibody for Reducing Memory and Learning Problems in Schizophrenia, Avicenna Journal of Medical Biotechnology (2018)

Style	Citing Format
MLA	Mohammadinejad P, et al.. "Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial." Annals of Pharmacotherapy, vol. 49, no. 9, 2015, pp. 953-961.
APA	Mohammadinejad P, Arya P, Esfandbod M, Kaviani A, Najafi M, Kashani L, Zeinoddini A, Emami SA, Akhondzadeh S (2015). Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. Annals of Pharmacotherapy, 49(9), 953-961.
Chicago	Mohammadinejad P, Arya P, Esfandbod M, Kaviani A, Najafi M, Kashani L, Zeinoddini A, Emami SA, Akhondzadeh S. "Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial." Annals of Pharmacotherapy 49, no. 9 (2015): 953-961.
Harvard	Mohammadinejad P et al. (2015) 'Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial', Annals of Pharmacotherapy, 49(9), pp. 953-961.
Vancouver	Mohammadinejad P, Arya P, Esfandbod M, Kaviani A, Najafi M, Kashani L, et al.. Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. Annals of Pharmacotherapy. 2015;49(9):953-961.
BibTex	@article{ author = {Mohammadinejad P and Arya P and Esfandbod M and Kaviani A and Najafi M and Kashani L and Zeinoddini A and Emami SA and Akhondzadeh S}, title = {Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial}, journal = {Annals of Pharmacotherapy}, volume = {49}, number = {9}, pages = {953-961}, year = {2015} }
RIS	TY - JOUR AU - Mohammadinejad P AU - Arya P AU - Esfandbod M AU - Kaviani A AU - Najafi M AU - Kashani L AU - Zeinoddini A AU - Emami SA AU - Akhondzadeh S TI - Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial JO - Annals of Pharmacotherapy VL - 49 IS - 9 SP - 953 EP - 961 PY - 2015 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract